Sarcoma and Bladder Cancer Awareness Month and Trial
July is the awareness month for both sarcoma and bladder cancers.
Sarcoma cancer is symbolized by a yellow ribbon, while a marigold/blue/purple ribbon is the symbol for bladder cancer awareness.
As the region’s largest, most comprehensive provider of clinical research and drug trials, New York Oncology Hematology would like to make you aware of clinical research trials related to these cancers.
We are currently participating in two related clinical trials:
Sarcoma: 12220 Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Bladder cancer: 13227 A Phase II Multicenter, single-arm study of MPDL3280A in patients with locally advanced or metastatic urothelial bladder cancer.
For more information about this or any other trial, please visit our Clinical Trials page or call the NYOH Research Department at: (518) 489-0044 ext. 1239
More information about sarcoma and bladder cancer:
According to the American Cancer Society, sarcoma is a type of cancer that develops from certain tissues, like bone or muscle. There are 2 main types of sarcoma: bone sarcomas and soft tissue sarcomas.
Bladder cancer occurs mainly in older people. About 9 out of 10 people with this cancer are over the age of 55. The average age at the time of diagnosis is 73. Men are about 3 to 4 times more likely to get bladder cancer during their lifetime than women.
Below is additional information from the American Cancer Society:
Risk Factors for Sarcoma Cancer
Risk Factors for Bladder Cancer
Cancer Research at NYOH
Working with The US Oncology Network, National Cancer Institute, Dana Farber Cancer Institute and private pharmaceutical companies, New York Oncology Hematology provides the largest, most comprehensive clinical trial operation in the region. Trials are administered to patients across NYOH’s offices.
Over the past twenty years, NYOH has played a pivotal role in the FDA approval process of 38 new anti-cancer drugs. With new trials added weekly, visit our full list or search trials for a specific cancer.